Decreased C-reactive protein levels in alzheimer disease

Journal of Geriatric Psychiatry and Neurology

Volumn 23, Issue 1, 2010, Pages 49-53

  O'Bryant, Sid E ^a,h   Waring, Stephen C ^b   Hobson, Valerie ^c   Hall, James R ^d   Moore, Carol B ^e   Bottiglieri, Teodoro ^f   Massman, Paul ^g   Diaz Arrastia, Ramon ^h  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b MARSHFIELD CLINIC   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

^d University of North Texas Health Science Center   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF HOUSTON   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; C reactive protein; Inflammation; Primary prevention; Treatment

Indexed keywords

C REACTIVE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEMENTIA; FEMALE; HUMANS; IMMUNOASSAY; LINEAR MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77149151874     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988709351832     Document Type: Article

References (37)

1. Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med. 1998 46 (8). 391-395.
2. Kuller LH, Tracy RP, Shaten J., Meilahn EN Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996 144 (6). 537-547.
3. Ridker PM, Buring JE, Shih J., Matias M., Hennekens CH Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women [see comment]. Circulation. 1998 98 (8). 731-733.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 342 (12). 836-843. (Pubitemid 30165206)
5. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of Creactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997 17 (6). 1121-1127.
6. Tracy RP Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. Am J Geriatr Cardiol. 2002 11 (2). 93-100.
7. Ford ES, Giles WH Serum C. -reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol. 2000 20 (4). 1052-1056.
8. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [see comment]. Circulation. 2003 107 (3). 499-511.
9. Yaffe K., Kanaya A., Lindquist K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004 292 (18). 2237-2242.
10. Dik MG, Jonker C., Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005 64 (8). 1371-1377.
11. Engelhart MJ, Geerlings MI, Meijer J., et al. Inflammatory proteins in plasma and the risk of dementia: The Rotterdam Study. Arch Neurol. 2004 61 (5). 668-672.
12. Schmidt R., Schmidt H., Curb JD, Masaki K., White LR, Launer LJ Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002 52 (2). 168-174. (Pubitemid 34810596)
13. Duong T., Nikolaeva M., Acton PJ C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimers disease. Brain Res. 1997 749 (1). 152-156.
14. Iwamoto N., Nishiyama E., Ohwada J., Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimers disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett. 1994 177 (1-2). 23-26.
15. Ravaglia G., Forti P., Maioli F., et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging. 2007 28 (12). 1810-1820. (Pubitemid 47539699)
16. van Oijen M., Witteman JC, Hofman A., Koudstaal PJ, Breteler MM Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke. 2005 36 (12). 2637-2641.
17. Gupta A., Watkins A., Thomas P., et al. Coagulation and inflammatory markers in Alzheimers and vascular dementia. Int J Clin Pract. 2004 59 (1). 52-57.
18. Locascio JJ, Fukumoto H., Yap L., et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008 65 (6). 776-785.
19. Waring S., OBryant SE, Reisch JS, Diaz-Arrastia R., Knebl J., Doody, R. for the Texas Alzheimers Research Consortium. The Texas Alzheimers Research Consortium longitudinal research cohort: study design and baseline characteristics. Texas Public Health J. 2008 60 (3). 9-13.
20. McKhann D., Drockman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group. Neurology. 1984 34 (7). 939-944.
21. Folstein MF, Folstein SE, McHugh PR Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 12 (3). 189-198.
22. Hughes CP, Berg L., Danziger WL, Coben LA, Martin RL A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 140: 566-572.
23. OBryant SE, Hobson V., Hall J., Lacritz L., Massman P., Cullum M., Diaz-Arrastia R. (2009). Brain-derived neurotropic factor (BDNF) in Alzheimers disease. A project of the Texas Alzheimers Research Consortium (TARC). Journal of Alzheimers Disease, 17 (2). 1051-1055.
24. Piccolomini F., LouWratten M., Sereni L., et al. Effects of the incubation in vitro with sorbents on serum proteomic pattern and cytokine concentration in cancer patients during chemotherapy- preliminary results. Biomed Pharmacother. 2006 60 (8). 463-467.
25. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J., Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008 155 (1). 56-61.
26. Duan H., Fleming J., Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 2008 58 (5). 1465-1474.
27. Delaleu N., Immervoll H., Cornelius J., Jonsson R. Biomarker profiles in serum and saliva of experimental Sjogrens syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther. 2008 10 (1). R22.
28. Diaz-Arrastia R., Moore CB, Arning E., Bottiglieri T. C-reactive protein in aging and Alzheimers disease: correlation with cerebral atrophy and low plasma vitamin B6. International Conference on Alzheimers Disease 2006 Madrid, Spain.
29. Whitmer RA, Sidney S., Selby J., Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005 64 (2). 277-281.
30. Galimberti D., Fenoglio C., Lovati C., et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimers disease. Neurobiol Aging. 2006 27 (12). 1763-1768.
31. Int Veld BA, Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimers disease. N Engl J Med. 2001 345 (21). 1515-1521.
32. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. 2000 54 (11). 2066-2071.
33. Etminan M., Gill S., Samii A. Effect of non-steroidal antiinflammatory drugs on risk of Alzheimers disease: systematic review and meta-analysis of observational studies. BMJ. 2003 327 (7407). 128.
34. Breitner J., Haneuse Sjpa, Walker R., et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009 72 (22). 1899-1905.
35. Aisen PS, Schafer KA, Grundman M., et al, for Alzheimers Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial [see comment]. JAMA. 2003 289 (21). 2819-2826.
36. Thal LJ, Ferris SH, Kirby L., et al, for the Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment [see comment]. Neuropsychopharmacology. 2005 30 (6). 1204-1215.
37. Lyketsos CG, Breitner JC, Green RC, et al, and the Adapt-Research-Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007 68 (21). 1800-1808.